Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis

CYP2C19 (*2, *3 loss-of-function alleles)

CYP2C19 intermediate (IM) and poor metabolizers (PM) → reduced clopidogrel activation → elevated residual platelet reactivity → MACE; prasugrel and ticagrelor bypass this metabolism

Meta-analysis combining data from major randomized trials (TAILOR-PCI n=5,302, POPular Genetics n=2,488, PHARMCLO n=888) on CYP2C19 genotyping for P2Y12 inhibitor choice post-PCI and in ACS. Contrasting results: Chinese meta-analyses show 31% MACE reduction with genotype-guided approach in Asian populations (CYP2C19*2/*3 ~30%), while TAILOR-PCI (international) shows no significant difference at 12 months (4.4% vs 5.3%; p=0.16). Heterogeneity reflects allele frequency differences between populations.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

CYP2C19 testing before PCI remains recommended by CPIC Level A and AHA 2024 to guide toward prasugrel or ticagrelor in PM and IM. Combined genotyping + platelet function testing strategy appears superior for high-thrombotic-risk patients. In European populations (CYP2C19*2 ~15%), the absolute benefit is more modest.

CPIC Level A (clopidogrel) +3; JACC meta-analysis (high impact) +2; 31% MACE reduction in Asian population +2; AHA 2024 recommends testing +1